Advanced search×

Existing antimalarial agents and malaria-treatment strategies

Expert Opin Pharmacother 10(8):1291-1306 (2009) PMID 19463069

In the absence of prompt and efficacious treatment, malaria patients may progress within a few hours from having minor symptoms to severe disease and death. These last years have seen the development of several artemisinin-based combinations, new treatments for severe malaria patients, and new strategies such as intermittent preventive treatment or the home-based/near-home management of malaria. The health sector is now confronted with several treatment options and strategies, in contrast with the period when chloroquine monotherapy was the standard treatment. The major challenge remains the large-scale deployment, in the most efficient way, of the tools available today, including artemisinin-based combination treatments, within health systems that remain extremely weak in malaria endemic countries, particularly in sub-Saharan Africa. Health system research, exploring new potential approaches for the large-scale implementation of these interventions, should be promoted in parallel with that on new therapeutic agents to be used in the unlucky event of the emergence and spread of artemisinin resistance. The prospects of substantially decreasing the malaria burden are brighter today than 20 - 30 years ago, but the efforts and resources committed to this purpose should be maintained over a long period.

Referenced by 1 articles

DOI: 10.1517/14656560902942319
Version: za2963e q8za4 q8zb8 q8zc4 q8zd0 q8ze1 q8zf5 q8zg8

Similar articles you may find interesting…

  1. Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longe...

    J Clin Med Res 5(3):217-21 (2013) PMID 23671547

    Several studies have shown the effectiveness of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for type 2 diabetes, with a hypoglycemic effect being demonstrated both when it is administered alone or in combination with other oral antidiabetic agents. However, there are few reports...
  2. Hydrophobic gentamicin loaded nanoparticles are effective in Brucella melitensis in mice.

    Antimicrob Agents Chemother (2013) PMID 23650167

    These results strongly suggest that PLGA nanoparticles containing chemically modified hydrophobic gentamicin may be a promising alternative for the treatment of human brucellosis....
  3. Survival rate of anti-TNF alpha treatments for psoriasis in routine dermatological practice: a multicenter observational study.

    Br J Dermatol (2013) PMID 23647206

    Adherence is an overall marker of treatment success, and it depends on multiple factors including efficacy and safety. Despite the large use of TNF alpha blockers in the treatment of plaque-type psoriasis, only few data regarding treatment adherence in routine clinical practice are available. OBJECT...